StreetInsider.com News Articles

StreetInsider.com News Articles http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 18 Aug 2026 06:00:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday BeOne Medicines renews CLL drug access deal for low-income nations http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html <p>BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.</p> <p>The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.</p> <p>Under the renewed terms, the partnership will continue operating in those three countries while http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html Tue, 18 Aug 2026 06:00:22 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines renews CLL drug access deal for low-income nations http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html <p>BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.</p> <p>The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.</p> <p>Under the renewed terms, the partnership will continue operating in those three countries while http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html Tue, 18 Aug 2026 06:00:22 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines renews CLL drug access deal for low-income nations http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html <p>BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.</p> <p>The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.</p> <p>Under the renewed terms, the partnership will continue operating in those three countries while http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html Tue, 18 Aug 2026 06:00:22 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines renews CLL drug access deal for low-income nations http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html <p>BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.</p> <p>The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.</p> <p>Under the renewed terms, the partnership will continue operating in those three countries while http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html Tue, 18 Aug 2026 06:00:22 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines renews CLL drug access deal for low-income nations http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html <p>BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.</p> <p>The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.</p> <p>Under the renewed terms, the partnership will continue operating in those three countries while http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html Tue, 18 Aug 2026 06:00:22 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines renews CLL drug access deal for low-income nations http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html <p>BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.</p> <p>The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.</p> <p>Under the renewed terms, the partnership will continue operating in those three countries while http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html Tue, 18 Aug 2026 06:00:22 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines renews CLL drug access deal for low-income nations http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html <p>BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.</p> <p>The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.</p> <p>Under the renewed terms, the partnership will continue operating in those three countries while http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html Tue, 18 Aug 2026 06:00:22 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines renews CLL drug access deal for low-income nations http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html <p>BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.</p> <p>The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.</p> <p>Under the renewed terms, the partnership will continue operating in those three countries while http://www.streetinsider.com/Corporate+News/BeOne+Medicines+renews+CLL+drug+access+deal+for+low-income+nations/26939848.html Tue, 18 Aug 2026 06:00:22 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Press+Releases/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html <p class="bwalignc"> <i>Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028</i> </p> <p> SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=b0b65bbb44854fe961bd073e7b8a300f" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2Fresponsibility%2Fgiving%2Fbeone-care-foundation%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Care+Foundation&index=2&md5=f706830b8b48c4d403887dd6b19294ac" shape="rect">BeOne Care Foundation</a>, a nonprofit charitable foundation, and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthemaxfoundation.org%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=The+Max+Foundation&index=3&md5=87bf3f75ebe468bb4e93d31356cc1545" shape="rect">The Max Foundation</a>, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic http://www.streetinsider.com/Business+Wire/BeOne+Medicines%2C+BeOne+Care+Foundation%2C+and+The+Max+Foundation+Renew+Partnership+to+Expand+Access+to+BRUKINSA%C2%AE+for+the+Treatment+of+Chronic+Lymphocytic+Leukemia+in+Low-+and+Middle-Income+Countries/26939825.html Tue, 18 Aug 2026 06:00:00 -0400 06160 688235 A.04109011 A.07953965 O.00963197 O.28981201 O.76306903 ONC Form 4 BeOne Medicines Ltd. For: Aug 11 Filed by: Lee Chan Henry http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Aug+11++Filed+by%3A+Lee+Chan+Henry/26923219.html si-local-file:///var/storage/secattach/20260813/26923219.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Aug+11++Filed+by%3A+Lee+Chan+Henry/26923219.html Thu, 13 Aug 2026 20:55:00 -0400 688235 O.76306903 ONC